Your browser doesn't support javascript.
loading
Mapping α2 adrenoceptors of the human brain with 11C-yohimbine.
Nahimi, Adjmal; Jakobsen, Steen; Munk, Ole L; Vang, Kim; Phan, Jenny A; Rodell, Anders; Gjedde, Albert.
Afiliação
  • Nahimi A; Department of Nuclear Medicine and PET Centre, Aarhus University Hospitals, Aarhus, Denmark anah@ki.au.dk.
  • Jakobsen S; Department of Nuclear Medicine and PET Centre, Aarhus University Hospitals, Aarhus, Denmark.
  • Munk OL; Department of Nuclear Medicine and PET Centre, Aarhus University Hospitals, Aarhus, Denmark.
  • Vang K; Department of Nuclear Medicine and PET Centre, Aarhus University Hospitals, Aarhus, Denmark.
  • Phan JA; Department of Nuclear Medicine and PET Centre, Aarhus University Hospitals, Aarhus, Denmark.
  • Rodell A; Department of Nuclear Medicine and PET Centre, Aarhus University Hospitals, Aarhus, Denmark.
  • Gjedde A; Department of Nuclear Medicine and PET Centre, Aarhus University Hospitals, Aarhus, Denmark Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland; and Department of Ne
J Nucl Med ; 56(3): 392-8, 2015 Mar.
Article em En | MEDLINE | ID: mdl-25635132
ABSTRACT
UNLABELLED A previous study from this laboratory suggested that (11)C-yohimbine, a selective α2-adrenoceptor antagonist, is an appropriate ligand for PET of α2 adrenoceptors that passes readily from blood to brain tissue in pigs but not in rodents. To test usefulness in humans, we determined blood-brain clearances, volumes of distribution, and receptor availability by means of PET with (11)C-yohimbine in healthy male adults.

METHODS:

We recorded the distribution of (11)C-yohimbine with 90-min dynamic PET and sampled arterial blood to measure intact (11)C-yohimbine in plasma. For analysis, we coregistered PET images to individual MR images and automatically identified 27 volumes of interest. We used 1-tissue-compartment graphical analysis with 6 linearized solutions of the fundamental binding equation, with the metabolite-corrected arterial plasma curves as input function, to estimate the kinetic parameters of (11)C-yohimbine. With the lowest steady-state distribution volume (VT), determined in the corpus callosum, we calculated the binding potential (receptor availability) of the radioligand in other regions.

RESULTS:

The linear regressions yielded similar estimates of the kinetic parameters. The cortical values of VT ranged from 0.82 mL cm(-3) in the right frontal cortex to 0.46 mL cm(-3) in the corpus callosum, with intermediate VT values in subcortical structures. Binding potentials averaged 0.6-0.8 in the cortex and 0.2-0.5 in subcortical regions.

CONCLUSION:

The maps of (11)C-yohimbine binding to α2 adrenoceptors in human brain had the highest values in cortical areas and hippocampus, with moderate values in subcortical structures, as found also in vitro. The results confirm the usefulness of the tracer (11)C-yohimbine for mapping α2 adrenoceptors in human brain in vivo.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ioimbina / Encéfalo / Radioisótopos de Carbono / Receptores Adrenérgicos alfa 2 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Humans / Male Idioma: En Revista: J Nucl Med Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Dinamarca

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ioimbina / Encéfalo / Radioisótopos de Carbono / Receptores Adrenérgicos alfa 2 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Humans / Male Idioma: En Revista: J Nucl Med Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Dinamarca